It is clear evidence that individuals diagnosed with obsessive-compulsive disorder (OCD) lack confidence in their memory and have low metamemory performance (judgment and accuracy). However, it is still unclear whether low metamemory performance is specific to first, domain general or domain specific, and second, to stimulus domain. To address these issues, we compared individuals diagnosed with OCD and healthy controls (HCs) on recognition, retrospective (judgments of learning [JOL]) and prospective (feeling of knowing [FOK]) metamemory judgments and under three different episodic memory tasks, which consisted of symptom-free, familiar and unfamiliar stimuli (word, scene, and face photo). OCD patients showed lower recognition performance, JOL and FOK judgments, and accuracy in all tasks than HCs. Also, OCD patients were slower than HCs during all cognitive performances. In both groups, metamemory performances were lower in familiar items than unfamiliar items. However, recognition performances were not affected by stimulus type. Our results support the idea of general episodic memory and a metamemory deficit in OCD. Moreover, metamemory deficits in OCD are domain general.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.beth.2023.07.002 | DOI Listing |
Chaos
January 2025
AIMdyn, Inc., Santa Barbara, California 93101, USA.
Koopman operator theory has found significant success in learning models of complex, real-world dynamical systems, enabling prediction and control. The greater interpretability and lower computational costs of these models, compared to traditional machine learning methodologies, make Koopman learning an especially appealing approach. Despite this, little work has been performed on endowing Koopman learning with the ability to leverage its own failures.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, North Rhine-Westphalia, Germany.
Background: MicroRNAs have been linked to dementia. However, understanding their relation to cognition in the general population is required to determine their potential use for the detection and prevention of age-associated cognitive decline and preclinical dementia. Therefore, we examined the association of circulating microRNAs with cognitive performance in a population-based cohort and the possible underlying mechanisms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Rush Alzheimer's Disease Center, Chicago, IL, USA.
Background: The recent approval of two anti-amyloid antibodies, Aducanamab and Lecanamab, have set the stage for the next generation of anti-amyloid treatments. Despite the capability of these treatments to lower Aβ brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Because eligibility for treatment includes individuals with MCI or mild dementia, that often harbor mixed pathologies, the cognitive impact of other brain pathologies may be important.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Rutgers University-Newark, Newark, NJ, USA.
Background: Alzheimer's disease (AD) is sometimes characterized as "type 3 diabetes" because hyperglycemia impairs cognitive function, particularly in the medial temporal lobe (MTL) and prefrontal regions. Further, both AD and type 2 diabetes (T2D) disproportionately impact African Americans. Although people with T2D are generally suggested to have lower episodic memory and executive function, limited data exist in older African Americans.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: New methods developed to estimate when AD biomarkers became abnormal in individuals have shown considerable heterogeneity in amyloid and tau pathology onset age. This work used polygenic scores (PGS) generated from CSF Aβ and ptau GWAS, individual-level genetic data, and estimated tau onset age (ETOA) to identify genetic influences on tau onset beyond APOE.
Method: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with genetic data, CSF biomarkers (Aβ and ptau), and longitudinal [F]Flortaucipir (FTP) tau PET were analyzed (N = 462).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!